Celldex Therapeutics, Inc.
Income Statement
| Line Item | FY2010 | FY2009 |
|---|---|---|
| Revenue | $46.8M | $15.2M |
| Cost of Revenue | — | — |
| Gross Profit | — | — |
| Gross Margin | — | — |
| Operating Expenses | ||
| Research & Development | $27.7M | $26.2M |
| SG&A Expense | $10.4M | $17.1M |
| Operating Income | $-6.5M | $-36.9M |
| Operating Margin | -13.8% | -242.8% |
| Interest Expense | $1.3M | $452.0K |
| Pretax Income | $-2.5M | $-37.1M |
| Income Tax Expense | — | $-529.0K |
| Net Income | $-2.5M | $-36.5M |
| Net Margin | -5.4% | -240.6% |
| EPS (Basic) | $0.00 | $0.00 |
| EPS (Diluted) | $0.00 | $0.00 |
| Shares Outstanding (Basic) | 65.84B | 40.95B |
| Shares Outstanding (Diluted) | 65.84B | 40.95B |
| Dividends Per Share | — | — |